Live Breaking News & Updates on Healthcare Canada

Stay updated with breaking news from Healthcare canada. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Celltrion gets priority review in Canada for Covid-19 drug regdanvimab


03 Aug 2021 (Last Updated August 3rd, 2021 12:44)
Celltrion filed new drug submission for the antibody treatment for rolling review in May.
Share Article
Regdanvimab lowered hospitalisation, oxygen need or death risk by 70% in Covid-19 patients versus placebo in Phase III trial. Credit: Dim Hou / Unsplash.
Health Canada has granted priority review to Celltrion Healthcare’s experimental monoclonal antibody, regdanvimab (CT-P59), for the treatment of Covid-19.
In May, Celltrion filed new drug submission (NDS) to the agency. The company noted that the screening phase was complete and the application has been accepted for review.
The rolling submission process aids the company to submit safety and efficacy data and information when they become available. ....

Jovan Antunovic , European Medicines Agency , Health Canada , Committee For Medicinal Products Human Use , Celltrion Healthcare , Healthcare Canada , Medicinal Products , Human Use , ஆரோக்கியம் கனடா , குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன் பயன்பாடு , சுகாதாரம் கனடா , மருத்துவ ப்ராடக்ட்ஸ் , மனிதன் பயன்பாடு ,